HHS Secretary Robert F. Kennedy Jr. to Headline Austin Eat Real Food Rally
AUSTIN, Texas, Feb. 24, 2026 /PRNewswire/ — Health and Human Services Secretary Robert F. Kennedy Jr. will deliver the keynote…
Read More
The Times Of Bengal
For You Forever Yours
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
THOUSAND OAKS, Calif., Feb. 24, 2026 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care…
Read More
Nektar Therapeutics to Participate in Two Investor Conferences in March
SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in…
Read More
VIPC Empowers Life Science Startup Company, Tiny Cargo, in Opening New $1.5 Million Manufacturing Facility in Roanoke
New Clean Room Manufacturing Plant Will Create Six New High-Paying Jobs in Local Community. ROANOKE, Va., Feb. 24, 2026 /PRNewswire/…
Read More
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team…
Read More
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect…
Read More
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON, Feb. 24, 2026 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair,…
Read More
Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases
DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment…
Read More
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company…
Read More
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 – –…
Read More
